Prescription Drug Monitoring Programs and Other State-Level Strategies
|
|
- Elijah Stevenson
- 5 years ago
- Views:
Transcription
1 Prescription Drug Monitoring Programs and Other State-Level Strategies Interventions to Reduce Opioid-Related Harms: Misuse, Abuse, Addiction, and Overdose Tamara M. Haegerich, PhD Acting Associate Director for Science Presentation at the National Academies of Sciences September 22, 2016 National Center for Injury Prevention and Control Division of Unintentional Injury Prevention
2 Evidence-Based State-Level Strategies 1 Prescription Drug Monitoring Programs Real time, mandated, and actively managed controlled substance centralized database accessible to providers 2 Public and Private Insurance Strategies Drug utilization review, lock-in programs, and prior authorization 3 Clinical Guidelines Recommendations based on the most recent scientific evidence and national guidelines 4 Legislation Pain clinic regulation, Good Samaritan laws * Naloxone distribution and access to Medication-Assisted Treatment are covered within other panel presentations and not considered herein
3 Summary of Available Research Evidence Few rigorous evaluations Assess knowledge/behavior rather than health outcomes Methodological limitations e.g., no comparison group, small samples, short-term Low quality of evidence Strategies identified are promising
4 Prescription Drug Monitoring Programs
5 PDMP System Overview
6 PDMP adoption Status of PDMPS September 2013 States with no PDMP Adapted from NAMSDL, Annual review of prescription drug monitoring programs. March
7 How can PDMPs be used? Surveillance and evaluation tool Clinical decision-making Law enforcement Regulation (state medical board)
8 Selected PDMP Best/Promising Practices Real time/reductions in data collection interval Universal registration and use Active management (proactive prescriber outreach; unsolicited reporting to regulatory boards) Collection of data on all controlled substances schedules Delegated access (e.g., NPs, PAs) Enabled access by appropriate users (e.g., public health, regulatory boards, law enforcement) Epidemiological analysis Integration with EHRs and HIEs Interstate data sharing Clark et al. (2012). Prescription Drug Monitoring Programs: An assessment of the evidence for best practices. PDMP Center of Excellence, Brandeis University.
9 Evidence for Effectiveness PDMPs Descriptive before-after and time series Mixed findings for prescribing prescribing schedule II; prescribing of schedule III Decrease in multiple prescribers and pharmacies Mixed findings for morbidity (e.g., ED visits) and mortality Patrick et al (2016): ITS 1.12 opioid-related overdose deaths per 100,000 population in year of implementation; greater reductions with higher numbers of drugs included and data updates at least weekly
10 Public and Private Insurance Strategies
11 Prior authorization Insurance Strategies Coverage requires review to ensure criteria met Drug utilization review Retrospective claims review to identify inappropriate prescribing Patient review and restriction Require patients to use one prescriber and/or pharmacy for controlled substance prescriptions
12 Evidence for Effectiveness Insurance Strategies Descriptive/before-after, time series, RCT Decrease in ED visits No changes in mortality Decrease in poly-pharmacy, high dosage, number of prescribers and pharmacies Gonzalez & Kolbasovsky (2012): RCT Comparing provider letter provision based on drug utilization review to resource provision; 24% in prescribers, 16% in pharmacies, 15% in filled prescriptions
13 Clinical Guidelines
14 Clinical Guideline Strategy Issued by federal, state, and national organizations CDC Guideline for Prescribing Opioids for Chronic Pain United States, 2016 Prescribing recommendations Initiation Dosing Monitoring (e.g., PDMP, UDT) Discontinuation Typically accompanied by implementation efforts Education (e.g., CME) Academic detailing
15 Evidence of Effectiveness Clinical Guidelines Descriptive before-after, time series, RCT Moderate knowledge improvements for providers Limited use of recommended practices, particularly without training and education efforts to support Some effects on dosing limits, ER/LA opioids, urine drug testing Decreases in ED visits and deaths Cochella & Bateman (2011): Pretest-posttest; after academic detailing with clinic presentations and translation materials, selfreported lowering initial dosages and slowing dose escalations and increased PDMP use; 14% overdose deaths Paone et al (2015): 29% opioid overdose deaths in Staten Island after comprehensive strategy with guideline at core
16 Legislation
17 Pain clinic regulation State Legislation Requires state oversight and contains requirements concerning ownership and operation (e.g., personnel requirements, inspection, license procedures) Good Samaritan laws Criminal immunity for help seeking; immunity for possession or administration of naloxone
18 Evidence of Effectiveness State Legislation Descriptive/before-after, time series Greater comfort calling 911 and greater likelihood of reporting behavior with immunity Reduction in pain clinics, opioid supply, overdose death rates after implementation of pain clinic law Johnson et al (2014) After regulation, overdose death rate 27%; prescribing declined for drugs where overdose death rate declined
19 Research Gaps How can PDMP data be best leveraged for surveillance and etiologic investigation? How could PDMP data be used for post-marketing surveillance of opioid medications? What systems-level translation and improvement strategies can enhance adoption and use of recommended clinical strategies, including PDMP use? Could inclusion of education on PDMP checks and CDC guideline recommendations more broadly in REMS improve use and utility? Which insurance/pbm interventions and state policies change prescribing behaviors most effectively while supporting effective pain management?
20 For more information please contact Centers for Disease Control and Prevention 1600 Clifton Road NE, Atlanta, GA Telephone: CDC-INFO ( )/TTY: Web: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
CDC s Approach to Addressing the Opioid Overdose Epidemic
CDC s Approach to Addressing the Opioid Overdose Epidemic Sarah Bacon National Center for Injury Prevention and Control Division of Unintentional Injury Prevention June 23, 2016 500,000 drug overdose deaths
More informationCDC Guideline for Prescribing Opioids for Chronic Pain
National Center for Injury Prevention and Control CDC Guideline for Prescribing Opioids for Chronic Pain John Halpin, MD, MPH Medical Officer Division of Unintentional Injury Prevention Prescription Drug
More informationAddressing Prescription Drug Abuse. Allan Coukell Senior Director, Drugs and Medical Devices The Pew Charitable Trust
Addressing Prescription Drug Abuse Allan Coukell Senior Director, Drugs and Medical Devices The Pew Charitable Trust Outline 1. Prescription Drug Monitoring Programs 2. Federal policy landscape including
More informationInterstate Variation in Prescribing of Opioid Pain Relievers and Benzodiazepines Karin A. Mack, PhD Associate Director for Science
Interstate Variation in Prescribing of Opioid Pain Relievers and Benzodiazepines Karin A. Mack, PhD Associate Director for Science National Center for Injury Prevention and Control Division of Analysis,
More informationIllinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program
Illinois Prescription Monitoring Program Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program Agenda Provide an overview of the Illinois Prescription Monitoring Program
More informationThe Prescription Drug Overdose Epidemic
The Prescription Drug Overdose Epidemic Rita Noonan, PhD National Center for Injury Prevention and Control Centers for Disease Control and Prevention National Center for Injury Prevention and Control Division
More informationCDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control
CDC Guideline for Prescribing Opioids for Chronic Pain Centers for Disease Control and Prevention National Center for Injury Prevention and Control THE EPIDEMIC Chronic Pain and Prescription Opioids 11%
More informationPerformance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)
Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and
More informationPrescription Opioid Overdose in Oregon: A public health perspective
Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,
More informationSUMMIT ON REDUCING THE SUPPLY OF ILLEGAL OPIOIDS IN WASHINGTON. Legislative Action: Opportunities and Challenges June 16, 2017
SUMMIT ON REDUCING THE SUPPLY OF ILLEGAL OPIOIDS IN WASHINGTON Legislative Action: Opportunities and Challenges June 16, 2017 Session Objectives Learn about laws adopted in other states to curtail the
More informationCDC Strategies for Protecting Older Americans
CDC Strategies for Protecting Older Americans Grant Baldwin, PhD, MPH Director, Division of Unintentional Injury Prevention National Center for Injury Prevention and Control Centers for Disease Control
More informationPDMP Track: Linking and Mapping PDMP Data. Gillian Leichtling Acumentra Health Chris Baumgartner, WA State Dept. of Health
PDMP Track: Linking and Mapping PDMP Data Gillian Leichtling Acumentra Health Chris Baumgartner, WA State Dept. of Health Disclosure Statement Gillian Leichtling and Chris Baumgartner have disclosed no
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis
More informationPrescription Monitoring Program Center for Excellence, Brandeis University. April 10-12, 2012 Walt Disney World Swan Resort
Prescription Monitoring Program Center for Excellence, Brandeis University April 10-12, 2012 Walt Disney World Swan Resort Accepted Learning Objectives: 1. Explain the current capabilities and contributions
More information4/10/2016. Legal & Policy Approaches to Reducing Opioid Poisonings. Overview. Background. Health Directors Legal Conference April 19, 2016
Legal & Policy Approaches to Reducing Opioid Poisonings Health Directors Legal Conference April 19, 2016 Corey Davis Network for Public Health Law Overview Fatal opioid overdose is at epidemic levels Many
More informationConfronting the Opioid Epidemic
Confronting the Opioid Epidemic Appropriately Treating Pain while Stopping Abuse Scott Kennedy, MD, Chief Medical Officer, Olympic Medical Center Ian Corbridge, RN, Clinical Policy Director, WSHA June
More informationInterventions in Prescription Opioid Abuse Do (or can) Prescription Monitoring Programs Make a Difference?
Interventions in Prescription Opioid Abuse Do (or can) Prescription Monitoring Programs Make a Difference? Richard C. Dart, MD, PhD Executive Director of RADARS System, Denver, Colorado Professor, University
More informationThe Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division
The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able
More informationPREVENTING PRESCRIPTION DRUG ABUSE AND OVERDOSE JUNE 23, 2016 SHERRY L. GREEN
PREVENTING PRESCRIPTION DRUG ABUSE AND OVERDOSE JUNE 23, 2016 SHERRY L. GREEN STATE LAW AND POLICY TRENDS STATE PRESCRIPTION DRUG MONITORING PROGRAMS (PMPS) Transformation into better health care tools
More informationOntario s Narcotics Strategy
Ontario s Narcotics Strategy Ontario Public Drug Programs Ministry of Health and Long-Term Care January 31, 2012 Ontario Harm Reduction Distribution Program Conference 2012 1 Background The Need for Action
More informationPrescription Drug Monitoring Program Update. Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017
Prescription Drug Monitoring Program Update Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017 Objectives Brief historical overview of opioids Review of PDMP information Discuss ideas from
More informationACCG Mental Health Summit
ACCG Mental Health Summit Sheila Pierce, Opioid Program Coordinator Director, Prescription Drug Management Program Discussion 1. Overview Opioid Problem in GA - Video 2. DPH Opioid Program 3. Priorities
More informationOpioids drive continued increase in drug overdose deaths
CDC: Drug overdose deaths increase for 11th consecutive year Opioids drive continued increase in drug overdose deaths Atlanta, GA, USA (February 20, 2013) - Drug overdose deaths increased for the 11th
More informationPresentation Objectives
Oregon s PDMP 101 Lisa Millet, MSH, Section Manager Injury and Violence Prevention Section Center for Prevention and Health Promotion Oregon Health Authority Eugene Oregon PDO Summit April 20, 2016 1 Presentation
More information5/16/2016. Roadmap. Legal Competencies. Prescription Drug Overdose at Epidemic Levels
Legal & Policy Approaches to Reducing Prescription Drug Overdose Disclaimer Funding for this activity was made possible (in part) by the Centers for Disease Control and Prevention. The views expressed
More informationPreventing Opioid Misuse in Texas
Preventing Opioid Misuse in Texas Kasey Strey, ACPS, SPF-Rx Project Director Jessica Duncan Cance, MPH, PhD, TTOR Lead Purpose Provide an overview of HHSC -funded opioid misuse prevention activities Discuss
More informationIt Takes A Village to Curb the Prescription Opioid Epidemic: Supply healthcare providers with resources to improve patient safety
Session L6 This presenter has nothing to disclose It Takes A Village to Curb the Prescription Opioid Epidemic: CDC Efforts Jan Losby, PhD Team Lead, Overdose Prevention Health Systems Team Division of
More informationThe STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018
The STOP Measure Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018 AHIP s Safe, Transparent Opioid Prescribing (STOP) Initiative Methodology
More informationMedicare Advantage Outreach and Education Bulletin
Medicare Advantage Outreach and Education Bulletin Blue Cross and Blue Shield of Georgia Prescription Drug Monitoring Programs Prescription drug abuse and diversion are acute problems in the area of pain
More informationPRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE
PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE September 20, 2013 Association of State and Territorial Health Officials Annual Meeting R. Gil Kerlikowske Director of National Drug Control Policy National
More informationOverview of Drug Overdose Good Samaritan Laws
Overview of Drug Overdose Good Samaritan Laws Presentation to the House Select Committee on Opioids & Substance Abuse Lara Lamprecht, DrPH Assistant Deputy Commissioner June 26, 2018 1 Presentation Overview
More informationProvider Education & Utilization Initiatives Alliance of States with PMPs East Regional Meeting
Provider Education & Utilization Initiatives Alliance of States with PMPs East Regional Meeting Baltimore, MD April 5, 2011 Massachusetts Department of Public Health MA Prescription Monitoring Program
More informationStrategies for Federal Agencies
Confronting Pain Management and the Opioid Epidemic Strategies for Federal Agencies Over the past 25 years, the United States has experienced a dramatic increase in deaths from opioid overdose, opioid
More informationTri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon. Executive Summary
Tri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon 2016 Executive Summary 20.8 million people in the United States have a substance use disorder (not limited to opioids), equivalent
More informationCDC Programmatic Activities in Breast and Ovarian Cancer Genomics
CDC Programmatic Activities in Breast and Ovarian Cancer Genomics Katrina F. Trivers, PhD, MSPH Epidemiologist Division of Cancer Prevention and Control CDC The First Line of Defense: Application of Breast
More informationPrescription Opioid Policies (22 March 2016)
Prescription Opioid Policies (22 March 2016) Prescription opioid misuse and abuse has become problematic in the United States and internationally in economically developed countries. Increased use of opioids
More informationProject Update: Comparing South Dakota Prescription Drug Monitoring Program Law Enforcement Profile Requests to Criminal History Data
Project Update: Comparing South Dakota Prescription Drug Monitoring Program Law Enforcement Profile Requests to Criminal History Data Presented to Bureau of Justice Assistance Harold Rogers Prescription
More informationSeptember 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201
September 1, 2017 The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Dear Secretary Price: The National Association of County
More informationReport to the Legislature: Unsolicited Reporting Criteria Established and Process Review MN Prescription Monitoring Program
This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp Minnesota Board of
More informationMonitoring Emergency Department Use for Dental Problems
Monitoring Emergency Department Use for Dental Problems Laurie Barker, MSPH National Oral Health Conference American Association for Community Dental Programs Annual Symposium April 29, 2012 National Center
More informationPennsylvania Prescription Drug Monitoring Program Trends,
DEA Intelligence Report Brief DEA-PHL-DIR-006-17 Pennsylvania Prescription Drug Monitoring Program Trends, 2014-2015 December 2016 1 Executive Summary The abuse and diversion of pharmaceutical drugs, particularly
More informationThe Regulatory Agency Will See You Now Kevin L. Zacharoff, MD Disclosures Nothing to Disclose
The Regulatory Agency Will See You Now Kevin L. Zacharoff, MD Disclosures Nothing to Disclose 1 Learning Objectives Identify pain treatment related regulatory agencies Discuss the changing role of regulatory
More informationPotential Solutions to Epidemic Substance Abuse in US and Europe
Potential Solutions to Epidemic Substance Abuse in US and Europe Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center, Denver Health 1 Professor, University of Colorado School of Medicine
More informationDecreasing the Harms from Prescription Drug Misuse: A Case for Pharmacists and Prescription Monitoring Programs
Decreasing the Harms from Prescription Drug Misuse: A Case for Pharmacists and Prescription Monitoring Programs Beth Sproule, BScPhm, PharmD Clinician Scientist Centre for Addiction and Mental Health &
More informationMARYLAND BOARD OF PHARMACY
MARYLAND BOARD OF PHARMACY CONTRACEPTION REGULATIONSAnd Other Legislative Initiatives THE ROAD FROM CONCEPTUALIZATION TO IMPLEMENTATION Deena Speights-Napata Executive Director Maryland Board of Pharmacy
More informationScaling the National Diabetes Prevention Program
Scaling the National Diabetes Prevention Program Kris Ernst, BSN, RN, CDE Private Sector Coordinator Division of Diabetes Translation Centers for Disease Control and Prevention National Center for Chronic
More informationState Action to Prevent and
State Action to Prevent and Treat Prescription Drug Abuse Paul Jarris, MD, MBA Executive Director Association of State and Territorial Health Officials Hearing from Each Other: State Reports NGA Policy
More informationArkansas Department of Health
Arkansas Department of Health 4815 West Markham Street Little Rock, Arkansas 72205-3867 Telephone (501) 661-2000 Governor Mike Beebe Nathaniel Smith, MD, MPH, Interim Director and State Health Officer
More informationWHAT YOU NEED TO KNOW TO ABOUT AB 474
WHAT YOU NEED TO KNOW TO ABOUT AB 474 PRESENTED BY: NEVADA STATE BOARD OF OSTEOPATHIC MEDICINE 2275 Corporate Circle, Suite 210 Henderson, NV 89074 702-732-2147 Fax 702-732-2079 Web Site: www.bom.nv.gov
More informationNorth Carolina, like the rest of the nation, has been experiencing
INVITED COMMENTARY The North Carolina Controlled Substances Reporting System: A Valuable Tool for Combating Prescription Drug Misuse William D. Bronson Prescription drug misuse is a growing problem that
More informationPrescription Monitoring Program (PMP)
06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid
More informationKANSAS Kansas State Board of Healing Arts. Source: Kansas State Board of Healing Arts. Approved: October 17, 1998
KANSAS Kansas State Board of Healing Arts Source: Kansas State Board of Healing Arts Approved: October 17, 1998 GUIDELINES FOR THE USE OF CONTROLLED SUBSTANCES FOR THE TREATMENT OF PAIN Section 1: Preamble
More informationThyroid cancer in the United States: Recent increases
Thyroid cancer in the United States: Recent increases Meg Watson Epidemiology and Applied Research Branch Division of Cancer Prevention and Control CDC NAACCR Annual Conference June 22, 2011 National Center
More information9/17/2018. Capstone Committee Chair Dr. Brenda Cassidy, DNP, RN, PCNP-PC Assistant Professor Health Promotion and Development
Evaluating Emergency Department Opioid Prescribing Behaviors after Education about Mandated Use of the Pennsylvania Prescription Drug Monitoring Program Jennifer Martello, DNP, RN, FNP-BC University of
More informationSuccessful Prevention Strategies to Address the Opioid Crises
Successful Prevention Strategies to Address the Opioid Crises Shannon Breitzman, MSW, Principal Denver Office Lindsey Kato, MPH, CHES, Consultant Denver Office 1 LEARNING OBJECTIVES + Find out how to effectively
More informationFrom Medicaid Transformation Approved Project Toolkit, June 2017
From Medicaid Transformation Approved Project Toolkit, June 2017 Domain 3: Prevention and Health Promotion Transformation projects within this domain focus on prevention and health promotion to eliminate
More informationHigh-Decile Prescribers: All Gain, No Pain?
High-Decile Prescribers: All Gain, No Pain? Len Paulozzi, MD, MPH National Center for Injury Prevention and Control Centers for Disease Control and Prevention National Center for Injury Prevention and
More informationOPIOID OVERDOSE EPIDEMIC: What Healthcare Providers Need to Know
OPIOID OVERDOSE EPIDEMIC: What Healthcare Providers Need to Know WHAT S NEW UPDATE CUMBERLAND, MD Renata J. Henry, M.Ed. Director, Central East ATTC March 16, 2016 Behavioral Health is Essential to Health
More informationINTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D
INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D SIXTY-THIRD REGULAR SESSION April 25-27, 2018 México D.F., México OEA/Ser.L/XIV.2.63 CICAD/doc.2385/18 25 April 2018 Original: English THE OPIOID
More informationAddressing the Opioid Epidemic in Tennessee
Addressing the Opioid Epidemic in Tennessee A Multidisciplinary Approach Melissa McPheeters, PhD, MPH Director, Informatics and Public Health Analytics 26 108 733 *Source: CDC References Centers for
More informationPDMP Tools to Identify Red Flag Situations
PDMP Tools to Identify Red Flag Situations Prescription Drug Monitoring Programs CBI Baltimore, MD February 7, 2017 Grant Carrow, Ph.D. Project Consultant The Heller School for Social Policy and Management
More informationUsing Cancer Registry Data for Post Marketing Surveillance of Rare Cancers
Using Cancer Registry Data for Post Marketing Surveillance of Rare Cancers Hannah K Weir, PhD Epidemiology and Applied Research Branch Division of Cancer Prevention and Control CDC NAACCR Annual Conference
More informationEmergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs --- United States,
Morbidity and Mortality Weekly Report (MMWR) Emergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs --- United States, 2004--2008 Weekly June 18, 2010 / 59(23);705-709 Rates
More informationReport to the Legislature: Recommendations on Required Use and Other Uses of the MN Prescription Monitoring Program Database
This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp Minnesota Board of
More informationOpioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices
Opioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices August 25, 2017 Presented by Michael Crooks, PharmD. Medication Safety and Care Coordination Task Lead 8/28/2017
More informationMortality Slide Series. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention
Mortality Slide Series National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention HIV Mortality Slides An analysis of trends in rates and distributions of deaths
More informationSTATE PRESCRIPTION DRUG MONITORING PROGRAMS (PMPS): A NATIONAL PERSPECTIVE
STATE PRESCRIPTION DRUG MONITORING PROGRAMS (PMPS): A NATIONAL PERSPECTIVE PRESENTATION ON BEHALF OF THE NATIONAL ASSOCIATION OF STATE CONTROLLED SUBSTANCES AUTHORITIES (NASCSA) BY SHERRY L. GREEN OVERVIEW
More informationAssociation of State and Territorial Health Officials (ASTHO)
Association of State and Territorial Health Officials (ASTHO) Strategy Session on Prescription Drug Misuse and Abuse Prepared by: August 13-14, 2013 Table of Contents Introduction... 1 Setting Future Direction
More informationLouisiana. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Louisiana Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationOverview of ASHP Opioid Efforts
Overview of ASHP Opioid Efforts Deborah A Pasko, Pharm.D, MHA Director, Medication Safety & Quality Nicholas Gentile Director, State Grassroots Advocacy and Political Action Presenter My educational background
More informationChallenges for U.S. Attorneys Offices (USAO) in Opioid Cases
Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases Overview On August 2, 2017, U.S. Attorney General Jeff Sessions announced a pilot program whereby a new federal data analysis program is being
More informationMedicare Advantage Outreach and Education Bulletin
Medicare Advantage Outreach and Education Bulletin Anthem Blue Cross and Blue Shield Prescription Drug Monitoring Programs Prescription drug abuse and diversion are acute problems in the area of pain management.
More informationRisk Classification Modeling to Combat Opioid Abuse
Risk Classification Modeling to Combat Opioid Abuse Improve Data Sharing to Identify High-Risk Prescribers of Opioids Christopher Sterling Chief Statistician NCI, Inc. www.nciinc.com 11730 Plaza America
More informationRe: Draft Guideline for Prescribing Opioids for Chronic Pain, 2016 [CDC ]
American Cancer Society Cancer Action Network 555 11 th Street, NW Suite 300 Washington, DC 20004 202.661.5700 www.acscan.org January 12, 2016 Tom Frieden, M.D., M.P.H. Director, Centers for Disease Control
More informationFDA s Response to the Opioid Crisis and the FDA Safe Use Initiative
FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative Scott K. Winiecki, MD Professional Affairs and Stakeholder Engagement Staff (PASES) Center For Drug Evaluation and Research (CDER) U.S.
More informationOverview from the Division of Cancer Prevention and Control
Overview from the Division of Cancer Prevention and Control Lisa C. Richardson, MD, MPH Director, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention (CDC) Advisory Committee
More informationMeth and Opioid Abuse Prevention Efforts
Meth and Opioid Abuse Prevention Efforts Prescription Drugs/Opioids in South Dakota Departments of Health and Social Services Drug Abuse in South Dakota South Dakota ranked 2 nd lowest in the nation for
More information4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update
Bureau of Professional Licensing MAPS Updates & Opportunities April 28, 2018 Presented by Andrew Hudson, Manager Haley Winans, Analyst Drug Monitoring Section Bureau of Professional Licensing BPL-MAPS@Michigan.gov
More informationCouncil for Outbreak Response: Healthcare-Associated Infections & Antibiotic-Resistant Pathogens (CORHA) HICPAC December 1, 2016
Council for Outbreak Response: Healthcare-Associated Infections & Antibiotic-Resistant Pathogens (CORHA) HICPAC December 1, 2016 National Center for Emerging and Zoonotic Infectious Diseases Division of
More informationData-Driven Prevention Initiative
Data-Driven Prevention Initiative Arturo Brito, MD,MPH Deputy Commissioner New Jersey Department of Health Pain, Pain Management & Opioid Epidemic Symposium Princeton, New Jersey December 2, 2016 Reducing
More informationEvaluation of the N.C. Prescription
Evaluation of the N.C. Prescription Drug Monitoring Program 2013 National Meeting of the Safe States Alliance and SAVIR MarianaGarrettson Garrettson, MPH Chris Ringwalt, DrPH UNC Injury Prevention Research
More informationNew Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers
CENTERS FOR MEDICARE & MEDICAID SERVICES New Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers Background CMS understands the magnitude of the nation s opioid epidemic and
More information10/19/2011. Burden. Capacity. Core Violence and Injury Prevention Program: Developing S.M.A.R.T. Objectives. Moving the Needle
Core Violence and Injury Prevention Program: Developing S.M.A.R.T. Objectives Christopher D. Jones, PhD Core VIPP Evaluation Team October 19, 2011 National Center for Injury Prevention and Control Division
More informationCDC s Efforts to End the Opioid Epidemic
Amy Insert Peeples, CIO Name MPA Here Deputy Director, National Center for Injury Prevention and Control NCSL Opioid Policy Fellows Kick Off CDC s Efforts to End the Opioid Epidemic The Epidemic in America
More informationHouse Committee on Energy and Commerce House Committee on Energy and Commerce. Washington, DC Washington, DC 20515
February 28, 2018 The Honorable Michael Burgess, M.D. The Honorable Gene Green Chairman Ranking Member Subcommittee on Health Subcommittee on Health House Committee on Energy and Commerce House Committee
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationWashington State PMP Data Mapping Project
Washington State PMP Data Mapping Project 2014 Category 3 Grant Harold Rogers Category 3 Grantee Meeting February 25, 2015 Washington State BACKGROUND: OPIOID ISSUES AND PLANNING 2 WA Unintentional Opioid
More informationMissouri Guidelines for the Use of Controlled Substances for the Treatment of Pain
Substances for the Treatment of Pain Effective January 2007, the Board of Healing Arts appointed a Task Force to review the current statutes, rules and guidelines regarding the treatment of pain. This
More informationSAFE OPIOID PRESCRIBING C.U.R.E.S. PROGRAM
Sorin Buga, MD Associate Clinical Professor Department of Supportive Care City of Hope National Medical Center SAFE OPIOID PRESCRIBING C.U.R.E.S. PROGRAM Click to edit Master Presentation Date Disclosure
More informationMOA: Practice Managers Program. Presented by: Kimber Debelak, CMC, CMOM, CMIS. May 17, zpain Management. & New Opioid Laws
MOA: Practice Managers Program Presented by: Kimber Debelak, CMC, CMOM, CMIS May 17, 2018 Pain Management & New Opioid Laws Objectives and Educational Statement Objectives To understand the need for new
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Effective Date: 04.18 Last Review Date: 04.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description
More informationASTHO President s Challenge 15 x 15: Reduce Prescription Drug
ASTHO President s Challenge 15 x 15: Reduce Prescription Drug Misuse and Deaths 15% by 2015 Terry Cline, Ph.D. Commissioner of Health Oklahoma Secretary of Health and Human Services Prescription drugs
More informationOpioid Review and MAT Clinic CDC Guidelines
1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are
More informationOPIOIDS IN JACKSON COUNTY A PUBLIC HEALTH PERSPECTIVE OPIOID AWARENESS COUNTY LEADERSHIP FORUM SHELLEY CARRAWAY, HEALTH DIRECTOR DATE
OPIOIDS IN JACKSON COUNTY A PUBLIC HEALTH PERSPECTIVE OPIOID AWARENESS COUNTY LEADERSHIP FORUM SHELLEY CARRAWAY, HEALTH DIRECTOR DATE LOCAL HEALTH DIRECTOR REGIONS For counties with low counts, regional
More informationUnderstanding the Opioid Crisis: What s at the Heart of the Matter?
National Center for Injury Prevention and Control Understanding the Opioid Crisis: What s at the Heart of the Matter? Sara Patterson Associate Director for Policy National Center for Injury Prevention
More informationADDRESSING THE OPIOID CRISIS:
ADDRESSING THE OPIOID CRISIS: Preventing Abuse and Ensuring Patients Receive the Right Care in the Right Setting September 2018 EXECUTIVE SUMMARY Every day, about 115 Americans die from opioid abuse. 1
More informationJuly 6, Scott Gottlieb, MD Commissioner U.S. Food and Drug Administration New Hampshire Avenue Silver Spring, MD 20993
Scott Gottlieb, MD Commissioner U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 RE: Draft Revisions to the Food and Drug Administration Blueprint for Prescriber Education
More informationMay 25, Drug Overdose Update & Response: Combatting Opioid Overdose
May 25, 2017 Drug Overdose Update & Response: Combatting Opioid Overdose Overview The Problem -Overdose in North Carolina (and a little nationally) -Other associated health threats PDAAC-NC s Response
More informationDaniel Blaney-Koen, JD July 2018
National overview: America s opioid epidemic Daniel Blaney-Koen, JD July 2018 National landscape AMA Opioid Task Force Policy efforts Barriers to care Reasons for optimism 2 Illicit fentanyl and heroin
More informationNew Guidelines for Opioid Prescribing
New Guidelines for Opioid Prescribing What They Mean for Elders with Chronic Pain Manu Thakral, PhD, ARNP Kaiser Permanente Washington Health Research Institute Kaiser Permanente Washington Health Research
More information